BNTX Dec 2025 95.000 call
| Previous close | 38.00 |
| Open | 34.30 |
| Bid | 30.30 |
| Ask | 33.00 |
| Strike | 95.00 |
| Expiry date | 2025-12-19 |
| Day's range | 34.15 - 38.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 116 |
Business WirePfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
NEW YORK & MAINZ, Germany, September 20, 2024--Pfizer Inc. (NYSE: PFE, "Pfizer") and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for the companies’ Omicron KP.2-adapted monovalent COVID-19 vaccine (COMIRNATY® KP.2) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The European Commission w
Barrons.comBioNTech Is More Than a Covid-19 Stock. It’s Having a Great September.
Recently BioNTech has been boosted a wave of enthusiasm over another company’s cancer drug, which has turned the biopharma industry upside down.
Investor's Business DailyHow BioNTech, Up 26% Over Four Days, Is Riding Summit's Coattails To A Recovery
BioNTech stock has climbed 26% over four days as the German biotech rides a round of cancer treatment success from Summit Therapeutics.
